Skip to content

AN2 Therapeutics, Inc.

ANTX

CIK 0001880438

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$36.49M
+31.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.16
+32.6% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$53.49M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
36.02M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings